Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
- PMID: 27720840
- DOI: 10.1053/j.gastro.2016.09.046
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
Abstract
Strategies for management of inflammatory bowel diseases are shifting from simple control of symptoms toward full control of these diseases (clinical and endoscopic remission), with the final aim of blocking their progression and preventing bowel damage and disability. New goals have been proposed for treatment, such as treat to target and tight control based on therapeutic monitoring and early intervention. For patients who achieve clinical remission, there is often interest in discontinuation of therapy due to safety or economic concerns. We review the evidence supporting these emerging paradigms, the reasons that early effective treatment can alter progression of inflammatory bowel diseases, the importance of examining objective signs of inflammation, and the safety of reducing treatment dosage. We also discuss recent findings regarding personalization of care, including factors that predict patient outcomes and response to therapies, as well as preventative strategies.
Keywords: Control; Dose; Efficacy; Intestine.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases.J Crohns Colitis. 2014 Sep;8(9):927-35. doi: 10.1016/j.crohns.2014.02.021. Epub 2014 Apr 6. J Crohns Colitis. 2014. PMID: 24713173 Review.
-
Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.J Crohns Colitis. 2020 Feb 10;14(2):254-266. doi: 10.1093/ecco-jcc/jjz131. J Crohns Colitis. 2020. PMID: 31403666 Free PMC article.
-
What changes in inflammatory bowel disease management can be implemented today?J Crohns Colitis. 2012 Feb;6 Suppl 2:S260-7. doi: 10.1016/S1873-9946(12)60506-6. J Crohns Colitis. 2012. PMID: 22463933 Review.
-
What Are the Targets of Inflammatory Bowel Disease Management.Inflamm Bowel Dis. 2018 Jul 12;24(8):1670-1675. doi: 10.1093/ibd/izy064. Inflamm Bowel Dis. 2018. PMID: 29697788 Review.
-
Nutritional Strategies in the Management of Adult Patients with Inflammatory Bowel Disease: Dietary Considerations from Active Disease to Disease Remission.Curr Gastroenterol Rep. 2016 Oct;18(10):55. doi: 10.1007/s11894-016-0527-8. Curr Gastroenterol Rep. 2016. PMID: 27637649 Review.
Cited by
-
Real-World Treatment Outcomes Associated With Early Versus Delayed Vedolizumab Initiation in Patients With Ulcerative Colitis.Crohns Colitis 360. 2024 Oct 22;6(4):otae061. doi: 10.1093/crocol/otae061. eCollection 2024 Oct. Crohns Colitis 360. 2024. PMID: 39502268 Free PMC article.
-
Framework of IBD Care Delivery Across Ages.J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii55-ii66. doi: 10.1093/ecco-jcc/jjae093. J Crohns Colitis. 2024. PMID: 39475083 Free PMC article.
-
Histologic improvement predicts endoscopic remission in patients with ulcerative colitis.Sci Rep. 2024 Aug 27;14(1):19926. doi: 10.1038/s41598-024-68372-0. Sci Rep. 2024. PMID: 39198522 Free PMC article.
-
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.Gastro Hep Adv. 2024 Mar 7;3(4):539-550. doi: 10.1016/j.gastha.2024.02.008. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39131711 Free PMC article.
-
Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey.J Clin Med. 2024 Apr 24;13(9):2510. doi: 10.3390/jcm13092510. J Clin Med. 2024. PMID: 38731039 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
